These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2468920)

  • 1. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Lewis RV; McMurray J; McDevitt DG
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):1-6. PubMed ID: 2468920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation.
    Lundström T; Moor E; Rydén L
    Am Heart J; 1992 Oct; 124(4):917-23. PubMed ID: 1356311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.
    Ang EL; Chan WL; Cleland JG; Moore D; Krikler SJ; Alexander ND; Oakley CM
    Br Heart J; 1990 Oct; 64(4):256-60. PubMed ID: 1977430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Molajo AO; Coupe MO; Bennett DH
    Br Heart J; 1984 Oct; 52(4):392-5. PubMed ID: 6148092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xamoterol improves the control of chronic atrial fibrillation in elderly patients.
    Lawson-Matthew PJ; McLean KA; Dent M; Austin CA; Channer KS
    Age Ageing; 1995 Jul; 24(4):321-5. PubMed ID: 7484490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between digoxin and atenolol in chronic atrial fibrillation].
    Lanas F; Salvatici R; Castillo G; Montecinos A; Stockins B; Molina E
    Rev Med Chil; 1995 Oct; 123(10):1252-62. PubMed ID: 8733316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
    Matsuda M; Matsuda Y; Yamagishi T; Takahashi T; Haraguchi M; Tada T; Kusukawa R
    Cardiovasc Res; 1991 Jun; 25(6):453-7. PubMed ID: 1889058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.
    David D; Segni ED; Klein HO; Kaplinsky E
    Am J Cardiol; 1979 Dec; 44(7):1378-82. PubMed ID: 41449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil.
    Botto GL; Bonini W; Broffoni T
    Clin Cardiol; 1998 Nov; 21(11):837-40. PubMed ID: 9825197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    J Cardiol; 1990; 20(3):755-65. PubMed ID: 2151866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.
    Lewis RV; Irvine N; McDevitt DG
    Eur Heart J; 1988 Jul; 9(7):777-81. PubMed ID: 3169046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.
    Lammers JW; Müller ME; Folgering HT; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.
    Molajo AO; Bennett DH; Marlow HF; Snow HM; Bastain W
    Br J Clin Pharmacol; 1987 Sep; 24(3):373-9. PubMed ID: 2889460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.
    McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG
    Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of verapamil and digoxin in the treatment of atrial fibrillation.
    Lewis R; Lakhani M; Moreland TA; McDevitt DG
    Eur Heart J; 1987 Feb; 8(2):148-53. PubMed ID: 3552680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitation of calcium blocking and membrane effects by intrinsic sympathomimetic activity.
    Smith HJ; Halliday SE; Briscoe MG; Snow HM
    Cardiovasc Res; 1984 Jan; 18(1):30-6. PubMed ID: 6141007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers.
    Sørensen EV; Jensen HK; Faergeman O
    Eur J Clin Pharmacol; 1991; 41(1):51-5. PubMed ID: 1685993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.
    Waller DG; Webster J; Sykes CA; Bhalla KK; Wray R
    Eur Heart J; 1989 Nov; 10(11):1003-10. PubMed ID: 2574108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.